Radcliffe Department of Medicine, Gene Medicine Research Group, Nuffield Division of Clinical Laboratory Science, Oxford, UK.
Radcliffe Department of Medicine, MRC Human Immunology Unit, MRC Weatherall Institute of Molecular Medicine, Oxford, UK.
Thorax. 2020 Dec;75(12):1112-1115. doi: 10.1136/thoraxjnl-2020-214656. Epub 2020 Sep 3.
When recombinant simian immunodeficiency virus (SIV) is pseudotyped with the F and HN glycoproteins from murine respiratory Sendai virus (rSIV.F/HN), it provides efficient lung cell targeting and lifelong transgene expression in the murine airways. We have shown that a single dose of rSIV.F/HN can direct stable expression of neutralising antibody against influenza in the murine airways and systemic circulation, and protects mice against two different influenza strains in lethal challenge experiments. These data suggest that rSIV.F/HN could be used as a vector for passive immunisation against influenza and other respiratory pathogens.
当重组猴免疫缺陷病毒(SIV)被假型化为鼠呼吸道仙台病毒(rSIV.F/HN)的 F 和 HN 糖蛋白时,它可以有效地靶向肺部细胞,并在小鼠气道中实现终身转基因表达。我们已经证明,单次剂量的 rSIV.F/HN 可以在小鼠气道和全身循环中稳定表达针对流感的中和抗体,并在致死性挑战实验中保护小鼠免受两种不同的流感株的侵害。这些数据表明,rSIV.F/HN 可以用作针对流感和其他呼吸道病原体的被动免疫的载体。